PT1718288E - Formulações sólidas de ospemifeno - Google Patents
Formulações sólidas de ospemifeno Download PDFInfo
- Publication number
- PT1718288E PT1718288E PT05708125T PT05708125T PT1718288E PT 1718288 E PT1718288 E PT 1718288E PT 05708125 T PT05708125 T PT 05708125T PT 05708125 T PT05708125 T PT 05708125T PT 1718288 E PT1718288 E PT 1718288E
- Authority
- PT
- Portugal
- Prior art keywords
- ospemifene
- solid formulations
- stereoisomer
- metabolite
- intra
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- LUMKNAVTFCDUIE-VHXPQNKSSA-N ospemifene Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-VHXPQNKSSA-N 0.000 title 1
- 229960003969 ospemifene Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000013583 drug formulation Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/783,024 US8642079B2 (en) | 2004-02-23 | 2004-02-23 | Solid formulations of ospemifene |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1718288E true PT1718288E (pt) | 2011-07-25 |
Family
ID=34861126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT05708125T PT1718288E (pt) | 2004-02-23 | 2005-01-19 | Formulações sólidas de ospemifeno |
Country Status (19)
Country | Link |
---|---|
US (2) | US8642079B2 (pt) |
EP (2) | EP2286806A1 (pt) |
JP (1) | JP4993203B2 (pt) |
CN (1) | CN1953741B (pt) |
AT (1) | ATE506054T1 (pt) |
AU (1) | AU2005215174B2 (pt) |
BR (1) | BRPI0507897B8 (pt) |
CA (1) | CA2554695C (pt) |
CY (1) | CY1111689T1 (pt) |
DE (1) | DE602005027540D1 (pt) |
DK (1) | DK1718288T3 (pt) |
ES (1) | ES2364970T3 (pt) |
MX (1) | MXPA06009546A (pt) |
NO (1) | NO341573B1 (pt) |
PL (1) | PL1718288T3 (pt) |
PT (1) | PT1718288E (pt) |
RU (2) | RU2675624C2 (pt) |
SI (1) | SI1718288T1 (pt) |
WO (1) | WO2005079777A1 (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4077320B2 (ja) | 2001-01-29 | 2008-04-16 | 塩野義製薬株式会社 | 5−メチル−1−フェニル−2−(1h)−ピリドンを有効成分として含有する医薬製剤 |
US8236861B2 (en) * | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
US8642079B2 (en) * | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
DK2275098T3 (da) | 2004-05-04 | 2012-08-20 | Hormos Medical Ltd | Hidtil ukendte orale formulationer af ospemifen |
US8758821B2 (en) * | 2004-05-04 | 2014-06-24 | Hormos Medical Ltd. | Oral formulations of ospemifene |
NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
US20070104743A1 (en) * | 2005-11-09 | 2007-05-10 | Hormos Medical Ltd. | Formulations of fispemifene |
CA2563690C (en) * | 2006-10-12 | 2014-10-07 | Pharmascience Inc. | Pharmaceutical compositions comprising intra- and extra- granular fractions |
WO2008099060A2 (en) | 2007-02-14 | 2008-08-21 | Hormos Medical Ltd | Methods for the preparation of fispemifene from ospemifene |
DK2121553T3 (da) | 2007-02-14 | 2012-07-23 | Hormos Medical Ltd | Fremgangsmåde til fremstillingen af terapeutisk værdi-fulde triphenylbutenderivater |
US20110028480A1 (en) * | 2008-04-01 | 2011-02-03 | Ocean 1 806, Llc | Orodispersable formulations of phosphodiesterase-5 (pde-5) inhibitors |
JP6174156B2 (ja) | 2012-10-19 | 2017-08-02 | フェルミオン オサケ ユキチュア | オスペミフェンの製造方法 |
CN104788300B (zh) * | 2014-01-22 | 2017-01-11 | 南京华威医药科技开发有限公司 | 欧司哌米芬多晶型 |
US20160000732A1 (en) * | 2014-07-02 | 2016-01-07 | Cadila Healthcare Limited | Oral pharmaceutical compositions of ospemifene |
US20160022604A1 (en) * | 2014-07-23 | 2016-01-28 | Cadila Healthcare Limited | Directly compressed ospemifene compositions |
US10138190B2 (en) | 2015-01-09 | 2018-11-27 | Glenmark Pharmaceuticals Limited | Process for preparation of ospemifene |
US10596118B2 (en) * | 2015-03-10 | 2020-03-24 | Shionogi, Inc. | Solid dispersions |
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
MX2019008506A (es) * | 2017-01-24 | 2019-10-30 | Omnigen Res L L C | Suplemento de alimento granulado y metodos para elaboracion y uso. |
CA3178769A1 (en) | 2020-05-18 | 2021-11-25 | Jonas Savmarker | New pharmaceutical composition for drug delivery |
CA3238850A1 (en) | 2021-11-25 | 2023-06-01 | Jonas Savmarker | Pharmaceutical composition comprising adrenaline |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4117121A (en) * | 1977-04-22 | 1978-09-26 | Hoffmann-La Roche Inc. | Method of increasing bile flow and decreasing lipid levels |
FI100692B (fi) | 1994-05-24 | 1998-02-13 | Leiras Oy | Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä |
GB9418067D0 (en) | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
US6562862B1 (en) * | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
US5597582A (en) * | 1995-09-12 | 1997-01-28 | Sanofi | Oral gel capsule formulation of 1,2,4-benzotriazine oxides |
AU718417B2 (en) * | 1995-11-14 | 2000-04-13 | Stockhausen Gmbh & Co. Kg | Water additive and method for fire prevention and fire extinguishing |
GB9604577D0 (en) * | 1996-03-04 | 1996-05-01 | Orion Yhtymae Oy | Serum cholesterol lowering agent |
FI101305B (fi) * | 1996-03-18 | 1998-05-29 | Map Medical Technologies Oy | Radiofarmaseuttisena aineena käyttökelpoiset radiojodatut bentsodiatse piini-johdannaiset ja niiden käyttö diagnostiikassa |
DE19653736C2 (de) * | 1996-12-12 | 2002-11-21 | Lancaster Group Gmbh | Kosmetisches Präparat mit Peptidzusatz |
RU2112504C1 (ru) * | 1996-12-24 | 1998-06-10 | Открытое акционерное общество "Нижегородский химико-фармацевтический завод" | Средство для лечения заболеваний предстательной железы "витапрост" |
JP2002521322A (ja) * | 1998-07-23 | 2002-07-16 | ノボ ノルディスク アクティーゼルスカブ | 安定な医薬製剤の製造のための湿式顆粒化方法 |
US6525084B2 (en) * | 1998-07-23 | 2003-02-25 | Novo Nordisk A/S | Stable pharmaceutical formulation |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6245352B1 (en) * | 1999-04-27 | 2001-06-12 | Eli Lilly And Company | Pharmaceutical formulation |
US6245819B1 (en) * | 2000-07-21 | 2001-06-12 | Hormos Medical Oy, Ltd. | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
US6838484B2 (en) * | 2000-08-24 | 2005-01-04 | University Of Tennessee Research Foundation | Formulations comprising selective androgen receptor modulators |
WO2002056903A2 (en) * | 2001-01-17 | 2002-07-25 | Praecis Pharmaceuticals Inc. | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
RU2177802C1 (ru) * | 2001-01-25 | 2002-01-10 | Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" | Тетрапептид, регулирующий функции предстательной железы, фармакологическое средство на его основе и способ его применения |
US20030055075A1 (en) * | 2001-07-13 | 2003-03-20 | Rubsamen Reid M. | Programmable controlled release injectable opioid formulation |
CA2458452C (en) * | 2001-08-10 | 2011-04-19 | Takeda Chemical Industries, Ltd. | Gnrh agonist combination drugs |
HUP0202719A3 (en) * | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
CN101406464A (zh) | 2002-06-06 | 2009-04-15 | 霍尔莫斯医疗有限公司 | 抑制女性萎缩或治疗或预防与女性萎缩相关的症状的方法 |
US7407965B2 (en) * | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
US8236861B2 (en) * | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
US8642079B2 (en) | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
US20060105045A1 (en) * | 2004-11-08 | 2006-05-18 | Buchanan Charles M | Cyclodextrin solubilizers for liquid and semi-solid formulations |
EA200700760A1 (ru) * | 2007-04-27 | 2008-08-29 | Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") | Средство для лечения заболеваний предстательной железы |
RU2430733C2 (ru) * | 2009-10-08 | 2011-10-10 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Фармацевтическая композиция для лечения заболеваний предстательной железы (варианты) |
-
2004
- 2004-02-23 US US10/783,024 patent/US8642079B2/en active Active
-
2005
- 2005-01-19 CN CN2005800049727A patent/CN1953741B/zh active Active
- 2005-01-19 AU AU2005215174A patent/AU2005215174B2/en not_active Ceased
- 2005-01-19 CA CA2554695A patent/CA2554695C/en active Active
- 2005-01-19 PL PL05708125T patent/PL1718288T3/pl unknown
- 2005-01-19 DE DE602005027540T patent/DE602005027540D1/de active Active
- 2005-01-19 EP EP10180718A patent/EP2286806A1/en not_active Withdrawn
- 2005-01-19 EP EP05708125A patent/EP1718288B1/en active Active
- 2005-01-19 JP JP2007500233A patent/JP4993203B2/ja active Active
- 2005-01-19 AT AT05708125T patent/ATE506054T1/de active
- 2005-01-19 PT PT05708125T patent/PT1718288E/pt unknown
- 2005-01-19 DK DK05708125.9T patent/DK1718288T3/da active
- 2005-01-19 SI SI200531330T patent/SI1718288T1/sl unknown
- 2005-01-19 WO PCT/FI2005/000037 patent/WO2005079777A1/en active Application Filing
- 2005-01-19 ES ES05708125T patent/ES2364970T3/es active Active
- 2005-01-19 RU RU2011112362A patent/RU2675624C2/ru not_active Application Discontinuation
- 2005-01-19 RU RU2006133902/15A patent/RU2423113C2/ru active
- 2005-01-19 BR BRPI0507897A patent/BRPI0507897B8/pt not_active IP Right Cessation
- 2005-01-19 MX MXPA06009546A patent/MXPA06009546A/es active IP Right Grant
-
2006
- 2006-09-20 NO NO20064262A patent/NO341573B1/no unknown
-
2011
- 2011-07-14 CY CY20111100689T patent/CY1111689T1/el unknown
-
2014
- 2014-01-30 US US14/168,842 patent/US20140220118A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2554695A1 (en) | 2005-09-01 |
EP1718288A1 (en) | 2006-11-08 |
RU2675624C2 (ru) | 2018-12-21 |
PL1718288T3 (pl) | 2011-10-31 |
RU2011112362A (ru) | 2012-10-10 |
CN1953741A (zh) | 2007-04-25 |
RU2423113C2 (ru) | 2011-07-10 |
CA2554695C (en) | 2013-03-05 |
ES2364970T3 (es) | 2011-09-19 |
US8642079B2 (en) | 2014-02-04 |
SI1718288T1 (sl) | 2011-09-30 |
ATE506054T1 (de) | 2011-05-15 |
JP2007523210A (ja) | 2007-08-16 |
MXPA06009546A (es) | 2007-04-10 |
DK1718288T3 (da) | 2011-08-01 |
DE602005027540D1 (de) | 2011-06-01 |
AU2005215174B2 (en) | 2010-06-03 |
BRPI0507897B1 (pt) | 2018-10-09 |
RU2006133902A (ru) | 2008-03-27 |
NO20064262L (no) | 2006-09-20 |
BRPI0507897A (pt) | 2007-07-24 |
CY1111689T1 (el) | 2015-10-07 |
AU2005215174A1 (en) | 2005-09-01 |
EP1718288B1 (en) | 2011-04-20 |
US20050187301A1 (en) | 2005-08-25 |
BRPI0507897B8 (pt) | 2021-05-25 |
CN1953741B (zh) | 2011-03-30 |
JP4993203B2 (ja) | 2012-08-08 |
WO2005079777A1 (en) | 2005-09-01 |
US20140220118A1 (en) | 2014-08-07 |
NO341573B1 (no) | 2017-12-04 |
EP2286806A1 (en) | 2011-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI1718288T1 (sl) | Trdna formulacija ospemifena | |
HUS1500030I1 (hu) | Eljárás az ospemifene biohasznosulásának javítására | |
WO2007117465A3 (en) | Indazole compounds | |
TW200714583A (en) | Substituted gamma lactams as therapeutic agents | |
PL1940249T3 (pl) | Nowe formulacje rozpuszczalnych w tłuszczach składników aktywnych o wysokiej biodostępności | |
WO2007084728A3 (en) | 2-imino-benzimidazoles | |
TW200728307A (en) | Novel spirochromanone derivatives | |
WO2007014124A3 (en) | High drug load formulations and dosage forms | |
WO2007099410A3 (en) | Formulations of fispemifene | |
IL195269A0 (en) | Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic | |
UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
WO2008136392A1 (ja) | 経口投与用製剤 | |
WO2006083841A3 (en) | Therapeutic esters | |
WO2006079077A3 (en) | Use of diltiazem or analogs thereof as modulators of ghrelin receptor | |
WO2004098594A3 (en) | Dosage form containing pantoprazole as active ingredient | |
SI1806130T1 (sl) | Trden farmacevtski sestavek ki obsega irbesartan | |
WO2008094912A3 (en) | Substituted gamma lactams as therapeutic agents | |
WO2004098577A3 (en) | Dosage form containing (s)-pantoprazole as active ingredient | |
MX2007015171A (es) | Formulacion que comprende farnesil dibenzodiazepinona y un tensoactivo farmaceuticamente aceptable. | |
WO2010056041A3 (ko) | 허혈 또는 허혈 재관류에 의해 유발되는 심장질환의 치료 및 예방을 위한 약제 조성물 | |
WO2009084835A3 (en) | Pharmaceutical composition for treatment and prevention of kidney diseases | |
WO2007047881A3 (en) | Method for treating neuropathic pain | |
EP1852119A4 (en) | PHARMACEUTICAL PREPARATION CONTAINING PHENOXAZINIUM DERIVATIVE AS ACTIVE INGREDIENT | |
WO2007052167A3 (en) | Stable composition for a pharmaceutical formulation containing olanzapine | |
EP1757593A4 (en) | THERAPEUTIC AGENT FOR NON-VIRAL HEPATITIS |